1.
腹腔镜二次肾盂成形术治疗复发性UPJO的文献回顾
Review of literatures as for re-do laparoscopic pyeloplasty for recurrent UPJO after failed pyeloplasty
| Author and year | No. of patients | Age/years | Prior surgery | Interval/months | Surgery approach | Surgery type | Mean operative time/min | Mean blood loss/mL | Mean hospital slay/days | Mean follow-up/ months | Postoperalive complications | Success rate* |
| OP, open pyeloplasty; RALP, robot-assisted laparoscopic pyeloplasty; LP, laparoscopic pyeloplasty; EP, endopyelotomy; BD, Balloon dilatation; N.D.，not determined; T, transperitoneal; A-H, Anderson-Hynes dismembered pyeloplasty; Y-V, Foley Y-V pyeloplasty; Z-plasty, zigzag plasty; LUC, laparoscopic ureterocalicostomy; UPJ, ureteropelvic junction; UTI, urinay tract infection; UPJO, ureteropelvie junction obstruetion; *success was defined as obstruction resolved and asymptomatic. Data are presented as mean ± SD, or median (mininuun -maximum). | ||||||||||||
| Piaggioet al. (2007)[32] | 6 | 7.5 (1.3-18.0) | 6 OP. 1 LP | N.D. | T | A-H | 290 (206-380) | N.D. | 2.5 (2-3) | 7 (1 -24) | N.D. | 83.3% (5/6) |
| Shepin et al.(2009)[5] | 9 | 30.5(19-50) | OP | 67.7(14-162) | T | 5 A-H. 3 Y_V, 1 Z-plasty | 204 (80-264) | 105 (20-300) | 2. 1 (2-3) | 66 (12-119) | None | 89% (8/9) |
| Zhou et al. (2011)[33] | 5 | 24.5 (19 -32) | OP | 93.6 (36-192) | T | A-H | 165 (105 -230) | 75 (50-120) | N. D. | 37.5 (33-49) | None | 100% |
| Abraham et al. (2015) [34] | 16 | 16.03 ±11.53 | 11 OP, 4 LP, 1 RALP | 3 -30 | T | 15 A-H, 1 LUC | 191.25 ±24.99 | N.D. | 3. 20 ±0.45 | 29.9 ±18.5 | N.D. | 93.3% (15/16) |
| Nishi et al. (2015) [26] | 13 | 26.0 (2 -47) | 4 OP. 2 LP, 4 EP. 3 BD | 23 (4 -396) | T | A-H | 269 (165 - 525) | 66 (20-230) | N. D. | 40 | lleus 1，hematuria 1, metal clip migration 1 | 92.3% (12/13) |
| Powell et al. (2015)[35] | 5 | 3.8 (1. 1 -9.3) | OP | N. D. | T | A-H | 90 (118 -282) | N.D. | 1.2 (1 -2) | 13 | None | 100% |
| Alnlel-Karim et al. (2016)[27] | 24 | 13.2 (5 - 17) | 22 OP, 2 LP | 23.6 (2 -38) | T | A-H | 211.4 ±32.2 | 102 ±35 | 4 (2-6) | 31.5 ±12.5 | Pnilongetl ileus 2, UFJ leakage 1, hmaturia 1, UTI 1 | 91.6% (22/24) |
| Cliianoone et al. (2017)[36] | 38 | 26.6 ±6.5 | 22 LP, 14 OP, 2 EP | N.D. | T | A-H | 103.16 ±30.00 | 122.37 ±73.25 | 4.47 ±0.86 | 42.5 ±24.6 | Hematuria 2, UTI 1, urine leakage 1 | 92.1% (35/38) |
| Hammady et al. (2017) [23] | 32 | 29 (18-65) | OP | 24 (10 - 38) | T | A-H | 110(90-155) | 42 (15 -120) | 1.3 (2-5) | 29.3 (20-32) | Urine leakage 2, hematuria 1, UTI 1 | 94. 4% (30/32) |
| Zhang et al. (2019) [25] | 14 | 34.71 ±10.50 | 105.6 (6 - 240) | T | A-H | 193.8 ±30.0 | N.D. | 9.79 ± 1.76 | 30.43 ±12.91 | Fever 1 | 85.7% (12/14) | |